- Current report filing (8-K)
2009年9月2日 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 1, 2009
MIDDLEBROOK PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50414
|
|
52-2208264
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
7 Village Circle, Suite 100, Westlake, Texas
|
|
76262
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(817) 837-1200
|
N/A
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01. Other Events.
On September 1, 2009, MiddleBrook Pharmaceuticals, Inc. issued a press release announcing a strategic realignment of
its field sales force, including a reduction in the number of sales
managers and field sales representatives by about 25 percent, to
approximately 225, and a reduction of its corporate staff by approximately 20 percent. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
|
|
|
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued September 1, 2009
|
2
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
MIDDLEBROOK PHARMACEUTICALS, INC.
|
|
|
|
Date: September 1, 2009
|
|
By:
/s/ Dave Becker
|
|
|
Dave Becker
|
|
|
Executive Vice President and Chief Financial Officer
|
3
3
INDEX TO EXHIBITS
|
|
|
Exhibit
|
|
Description
|
99.1
|
|
Press Release issued September 1, 2009
|
4
4
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
過去 株価チャート
から 4 2024 まで 5 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Middlebrook Pharmaceuticals (MM) (ナスダック市場): 0 recent articles
その他のニュース記事